

DAFTAR PUSTAKA

- Agbaji, O. O., *et.al.* (2019). Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults. *Journal of the International Association of Providers of AIDS Care*, 18, 2325958218821963. <https://doi.org/10.1177/2325958218821963>
- Astari,Linda ; Sawitri; Yunia Eka Safitri ; Desy Hinda P. (2009). Viral load pada Infeksi HIV. Departemen Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokteran Universitas Airlangga .Berkala Ilmu Kesehatan 21(1). Available at : <http://journal.unair.ac.id/filerPDF/Viral%20Load%20Vol%2021%20No%201.pdf>
- Badan Pusat Statistik Provinsi Papua. (2023). *Faktor-Faktor Yang Mempengaruhi Keputusan Perempuan Bekerja Di Papua*. Diakses pada 24 September 2024, dari <https://papua.bps.go.id/id/publication/2023/07/10/6084f4e63e5537e392b2a119/faktor-faktor-yang-mempengaruhi-keputusan-perempuan-bekerja-di-papua.html>
- Bosinger SE, and Utay NS (2015). Type I interferon: understanding its role in HIV pathogenesis and therapy. *Curr. HIV/AIDS Rep* 12, 41–53. Available at : <https://pubmed.ncbi.nlm.nih.gov/25662992/>
- CDC.(2021). *AIDS and Opportunistic infections*. Centers for Disease Control and Prevention. Available at : <https://www.cdc.gov/HIV/basics/livingwithHIV/opportunisticinfections.html>
- Choudhary MC, Mellors JW. (2022) . The transformation of HIV therapy: One pill once a day. *Antiviral Therapy*;27(2). doi:10.1177/13596535211062396.
- Costa, B., & Vale, N. (2022). Efavirenz: History, Development and Future. *Biomolecules*, 13(1), 88. <https://doi.org/10.3390/biom13010088> .
- Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 2024/05/08.
- Ditjen P2P Kemenkes RI .(2021). Laporan perkembangan HIV – AIDS dan Penyakit Infeksi Menular Seksual (PIMS).
- Eggleton dan Nagalli. (2023) . Highly Active Antiretroviral Therapy (HAART) . In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554533/> .

- Fitrianingsih, F., Ersa, C. B., Indriyani, D., & Wirdayanti, W. (2022). Gambaran Karakteristik Pasien Hiv Di Poli Rawat Jalan Rsud Raden Mattaher Jambi. *Jurnal Ilmiah Ilmu Terapan Universitas Jambi*, 6(2), 164-172. <https://mail.online-journal.unja.ac.id/JIITUJ/article/view/6131>
- Food and Drug Administration (FDA). (2019). *Highlight of Prescribing Information of Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate*. Available from : https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/210787PI.pdf
- Food and Drug Administration (FDA). (2021). *Highlight of Prescribing Information of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate*. Available from : https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/210787PI.pdf
- Ford, N., Meintjes, G., Vitoria, M., Greene, G., & Chiller, T. (2017). The evolving role of CD4 cell counts in HIV care. *Current Opinion in HIV and AIDS*, 12, 123–128. <https://doi.org/10.1097/COH.0000000000000348>.
- Hurbans, N., & Naidoo, P. (2024). Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study. *BMC infectious diseases*, 24(1), 343. <https://doi.org/10.1186/s12879-024-09202-6>
- Jóźwik, I. K., Passos, D. O., & Lyumkis, D. (2020). Structural Biology of HIV Integrase Strand Transfer Inhibitors. *Trends in pharmacological sciences*, 41(9), 611–626. <https://doi.org/10.1016/j.tips.2020.06.003>
- Juhaefah, A. J. A. (2020). Gambaran Karakteristik Pasien Hiv/Aids Yang Mendapat Antiretroviral Therapy (Art). *Jurnal Medika: Karya Ilmiah Kesehatan*, 5(1). <http://jurnal.itkeswhs.ac.id/index.php/medika/article/view/114>
- Justiz dan Naik. (2023). HIV-1–Associated Opportunistic Infections. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK539787/>
- Kemenkes RI. (2017). Program Pengendalian HIV AIDS dan PIMS di Fasilitas Kesehatan Tingkat Pertama. Direktorat Jendral Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. Available at : <https://repository.kemkes.go.id/book/687>
- Kemenkes RI. (2021) . PETA *GENOTYPING* HIV-1 PAPUA DAN PAPUA BARAT. Jakarta : Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan (LPB). ISBN 978-602-373-191-6. Available at : https://repository.badankebijakan.kemkes.go.id/id/eprint/4302/1/Buku%20Genotyping%20HIV_2021.pdf
- Kemenkes RI.(2023). Laporan Tahunan HIV/AIDS2022. Available at : http://p2p.kemkes.go.id/wp-content/uploads/2023/06/FINAL_6072023_Layout_HIVAIDS-1.pdf

- Kemnic TR, Gulick PG. 2022 . HIV Antiretroviral Therapy. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK513308/>
- Kepmenkes RI.(2019). Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/90/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana HIV. Available at : https://siha.kemkes.go.id/portal/files_upload/PNPK_HIV_Kop_Garuda__1_.pdf
- Kouamou, V., Machezano, R., Mapangisana, T., Maposhere, C., Munyati, S., Mutsvangwa, J., Shamu, T., McCarty, K., Katzenstein, D., & Manasa, J. (2022). *Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. AIDS research and human retroviruses*, 38(10), 774–778. <https://doi.org/10.1089/AID.2021.0140> . Available at : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634981/>
- Kurniawati, Y. (2023). PENGARUH TINGKAT PENDIDIKAN DENGAN KEJADIAN HIV/AIDS. *Jurnal Bidan Pintar*, 3(2). <https://doi.org/10.30737/jubitar.v3i2.1674>
- Lecher, S. L. *et.al.* (2021). HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. *MMWR. Morbidity and mortality weekly report*, 70(21), 775–778. <https://doi.org/10.15585/mmwr.mm7021a2>
- Mahale, P. R., Patel, B. S., & Kasmani, N. 2023. Treatment Outcomes of Dolutegravir-Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV. *Cureus*, 15(6), e40139. <https://doi.org/10.7759/cureus.40139>
- Mallampati, Divya MD, MPH; Ford, Nathan MPH, PhD, FRCPE; Hanaford, Alisse BS; Sugandhi, Nandita MD; Penazzato, Martina MD, PhD. (2017) Performance of Virological Testing for Early Infant Diagnosis: A Systematic Review. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 75(3):p 308-314 | DOI: 10.1097/QAI.0000000000001387 .
- Mariam, S. (2010). Perbandingan Respon Penderita Candidiasis HIV terhadap Antiretroviral.
- Meireles et.al .2019. Comparative effectiveness of first-line Antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir. *AIDS* 33(10):p 1663-1668, DOI:10.1097/QAD.0000000000002254
- Moretti, S., Schietroma, I., Sberna, G., Maggiorella, M. T., Sernicola, L., Farcomeni, S., Giovanetti, M., Ciccozzi, M., & Borsetti, A. (2023). HIV-1-Host Interaction in Gut-Associated Lymphoid Tissue (GALT): Effects on Local Environment and Comorbidities. *International journal of molecular sciences*, 24(15), 12193. <https://doi.org/10.3390/ijms241512193>

- Muema DM, Akilimali NA, Ndumnego OC, Rasehlo SS, Durgiah R, Ojwach DBA, Ismail N, Dong M, Moodley A, Dong KL, et al. (2020). Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. *BMC Med.* 18, 81. Available at : <https://pubmed.ncbi.nlm.nih.gov/32209092/>
- Novita, D. I., Karo, M. B., Tambaip, T., & Ekawati, E. A. (2022). Prevalensi dan Karakteristik Pasien Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) Di Kabupaten Merauke Periode Tahun 1992-2021. *SEMILAR NASIONAL PENELITIAN DAN PENGABDIAN 2022 - "Sukseskan Transformasi Kesehatan Melalui Inovasi Dan Implementasi Penelitian Dan Pengabdian Kepada Masyarakat Dalam Mewujudkan Universal Health Coverage (UHC) 2030."* <https://ejurnal2.poltekkestasikmalaya.ac.id/index.php/prosidingpenelitian/article/view/111/51>
- Novitry, F., & Tiara Sari. (2024). Risk Factor Analysis of HIV/AIDS Incidence in General Hospital. *Lentera Perawat*, 5(2), 349-360. <https://doi.org/10.52235/lp.v5i2.395>
- Nurwidia Arum, M. J., Kartiningrum, E. D., & Fardiansyah, A. (2019). ANALISIS SURVIVAL PENDERITA HIV/AIDS DI RSUD PROF. DR. SOEKANDAR KABUPATEN MOJOKERTO. *Hospital Majapahit (JURNAL ILMIAH KESEHATAN POLITEKNIK KESEHATAN MAJAPAHIT MOJOKERTO)*, 11(1), 47-59. <https://doi.org/10.5281/zenodo.3514656>
- NYOKO, Y. O., HARA, M. K., & ABSELIAN, U. P. (2017). KARAKTERISTIK PENDERITA HIV/AIDS DI SUMBA TIMUR TAHUN 2010-2016. *JKP (Jurnal Kesehatan Primer)*, 1(1), 4-15. <https://doi.org/10.5281/jkp.v1i1.21>
- Panel Ahli HIV/AIDS dan PIMS. Rekomendasi ART terbaru termasuk penggunaan DTG. Juli 2020
- Parekh, B. S., Ou, C. Y., Fonjungo, P. N., Kalou, M. B., Rottinghaus, E., Puren, A., Alexander, H., Hurlston Cox, M., & Nkengasong, J. N. (2019). Diagnosis of Human Immunodeficiency Virus Infection. *Clinical microbiology reviews*, 32(1), e00064-18. <https://doi.org/10.1128/CMR.00064-18> .
- Permenkes RI (2015). Peraturan Menteri Kesehatan No.87 tahun 2015 Pedoman Pengobatan Antiretroviral. Kementerian Kesehatan, Jakarta Indonesia
- Permenkes RI. (2022). PERATURAN MENTRI KESEHATAN REPUBLIK INDONESIA NOMOR 23 TAHUN 2022 TENTANG PENAGNNGGULANGAN HUMAN IMMUNODEFICIENCY VIRUS, ACQUIRED IMMUNODEFICIENCY SYNDROME, DAN INFEKSI MENULAR SEKSUAL

- Permenkes RI.(2014). Peraturan Menteri Kesehatan RI No. 87 tahun 2014 tentang Pedoman Pengobatan Antiretroviral.
- Prawira, Y., & Uwan, W. B. (2019). Karakteristik penderita infeksi HIV/AIDS di klinik voluntary counseling and testing Lazarus RS St. Antonius Pontianak tahun 2017. *Jurnal Cerebellum*, 5(4A), 1519-1533. <https://jurnal.untan.ac.id/index.php/JC/article/view/43017>
- RAHMAWATI, D., DINIARTI, F., & SYAFRIE, I. (2023). HUBUNGAN UMUR, JENIS KELAMIN, DAN RIWAYAT INFEKSI MENULAR SEKSUAL (IMS) DENGAN KEJADIAN HIV/AIDS DI WILAYAH KERJA PUSKESMAS PENURUNAN KOTA BENGKULU TAHUN 2022. *Journal of Nursing and Public Health*, 11(1), 293-300. <https://doi.org/10.37676/jnph.v11i1.4144>
- Rohmatullailah D, Fikriyah D. Faktor risiko kejadian HIV pada usia kelompok produktif di Indonesia. *Jurnal Biostatistik, Kependudukan, dan Informatika Kesehatan (BIKFOKES)*. (2021) 2:45–59. doi: 10.51181/bikfokes.v2i1.4652
- Saktina, P. U., & Satriyasa, B. K. (2017). Karakteristik penderita AIDS dan infeksi oportunistik di Rumah Sakit Umum Pusat Sanglah Denpasar periode juli 2013 sampai juni 2014. *E-Jurnal Medika Udayana*, 6(3), 1-6. <http://download.garuda.kemdikbud.go.id/article.php?article=1357501&val=970&title=KARAKTERISTIK%20PENDERITA%20AIDS%20DAN%20INFEKSI%20OORTUNISTIK%20DI%20RUMAH%20SAKIT%20UMUM%20PUSAT%20SANGLAH%20DENPASAR%20PERIODE%20JULI%202013%20SAMPAI%20JUNI%202014>
- Schröter, Juliane et.al. 2020 .Time to Viral Suppression in Perinatally HIV-Infected Infants Depends on the Viral load and CD4 T-Cell Percentage at the Start of Treatment. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 83(5):p 522-529, 2020. | DOI: 10.1097/QAI.0000000000002291
- Seitz dan Ehrlich .2016. Human Immunodeficiency Virus (HIV). German Advisory Committee Blood (Arbeitskreis Blut), Subgroup ‘Assessment of Pathogens Transmissible by Blood’, 43(3), 203–222. <https://doi.org/10.1159/000445852>.
- Semengue, et.al . 2022 . Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model. *Viruses*, 15(1), 18. <https://doi.org/10.3390/v15010018>
- Sereti, I., Krebs, S. J., Phanuphak, N., Fletcher, J. L., Slike, B., Pinyakorn, S., O'Connell, R. J., Rupert, A., Chomont, N., Valcour, V., Kim, J. H., Robb, M. L., Michael, N. L., Douek, D. C., Ananworanich, J., Uday, N. S., & RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 protocol teams (2017). Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy

- in Acute HIV Infection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*, 64(2), 124–131. <https://doi.org/10.1093/cid/ciw683> Available at : <https://pubmed.ncbi.nlm.nih.gov/27737952/>
- Silva, G. J. D., Mendicino, C. C. P., Pádua, C. A. M., & Tupinambás, U. (2023). Suppression of HIV in the first 12 months of Antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens. *Einstein (Sao Paulo, Brazil)*, 21, eAO0156. https://doi.org/10.31744/einstein_journal/2023AO0156 .
- Siska Mutiara Hikmah S, Hasri Kuswiharyanti, Vidi Ahmad Raafi, Ninik Juarti, & Tria Amaliadiana. (2021). Pengaruh Terapi ARV untuk Meningkatkan Kualitas Hidup Pasien HIV/AIDS: A Literature Review. *Journal of Bionursing*, 3(2), 134-145. <https://doi.org/10.20884/1.bion.2021.3.2.101> . Available at :
- Sugiyono. (2007). *Metode Penelitian Kuantitatif, Kualitatif dan R&D*. Bandung : Alfabeta
- Susanti, D. (2023). *Perbandingan Efektivitas Dan Keamanan Antara Paduan Regimen Tld (Tenofovir+ Lamivudin+ Dolutegravir) Dan Tle (Tenofovir+ Lamivudin+ Efavirens) Pada Pasien HIV* (Doctoral dissertation, Universitas Gadjah Mada).
- Syafirah. 2020. "Gambaran Pemberian Regimen Antiretroviral pada Pasien HIV/AIDS di RSP Dr.M.Djamil Padang Tahun 2017". *Jurnal FK Unand* : Vol.9 : 1s Available at: <http://jurnal.fk.unand.ac.id/index.php/jka/article/view/1169/1055>
- Taylor K, Fritz K, Parmar M. (2023). Lamivudine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559252/>
- Tongtong, Y., Shenghua, H., Yin, W., Lin, C., Huanxia, L., Chunrong, L., Ruifeng, Z., Xiaojing, Y., Yuan, Y., Yuanhong, H., & Ke, Y. (2022). Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study. *Journal of acquired immune deficiency syndromes (1999)*, 91(S1), S1–S7. <https://doi.org/10.1097/QAI.0000000000003041> .
- Twimukye, A., Laker, M., Odongpiny, E.A.L. *et al.* Patient experiences of switching from Efavirenz- to Dolutegravir-based Antiretroviral therapy: a qualitative study in Uganda. *BMC Infect Dis* 21, 1154 (2021). <https://doi.org/10.1186/s12879-021-06851-9>
- UNAIDS. (2023). *Global HIV & AIDS statistics - fact sheet*. Available at: <https://www.unaids.org/en/resources/fact-sheet>
- UNAIDS. (2024). *Undetectable=Untransmittable public health and HIV Viral load Supression*. Available at:

https://www.unaids.org/sites/default/files/media_asset/undetectable-untransmittable_en.pdf

United Nation. (2023). *SDG indicator metadata - UNSD*. United Nation Sustainable Development. Available at: . <https://unstats.un.org/sdgs/metadata/files/Metadata-03-01-01.pdf>

Vogler, I. H., Alfieri, D. F., Gianjacomio, H. D. B., Almeida, E. R. D., & Reiche, E. M. V. (2018). Safety of monitoring Antiretroviral therapy response in HIV-1 infection using CD4+ T cell count at long-term intervals. *Cadernos de saude publica*, 34(10), e00009618. <https://doi.org/10.1590/0102-311X00009618> .

Volberding, P. 2012. *Sande's HIV/AIDS Medicine* (2nd ed.). Elsevier.

Wassner, C., Bradley, N., & Lee, Y. (2020). A Review and Clinical Understanding of *Tenofovir*: *Tenofovir* Disoproxil Fumarate versus *Tenofovir* Alafenamide. *Journal of the International Association of Providers of AIDS Care*, 19, 2325958220919231. <https://doi.org/10.1177/2325958220919231> .

Waymack JR, Sundareshan V. Acquired Immune Deficiency Syndrome. [Updated 2023 May 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK537293/>

Weichseldorfer, M. *et.al.* (2021). Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients. *Pharmaceutics*, 13(11), 1798. <https://doi.org/10.3390/pharmaceutics13111798>

Weld E. D. (2021). Limits of Detection and Limits of Infection: Quantitative HIV Measurement in the Era of U = U. *The journal of applied laboratory medicine*, 6(1), 324–326. <https://doi.org/10.1093/jalm/jfaa176>

WHO.(2016).Consolidated Guidelines on the use of Antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd edition (2nd ed.). World Health Organization. Available at : <https://www.who.int/publications/i/item/9789241549684>

WHO.(2019). Update of recommendation on first- and second- line antiretroviral regimens policy brief. World Health Organization. Available at; <https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15>

WHO.(2021).Consolidated Guidelines on HIV pervention, testing, treatment, service delivery and monitoring : Recommendations for a public health approach. World Health Organization. Available at : <https://www.who.int/publications/i/item/9789240031593>

WHO.(2022).Update on the Transition to Dolutegravir-base Antiretroviral Therapy: Report of a WHO Meeting. World Health Organization. Available at :

<https://iris.who.int/bitstream/handle/10665/360836/9789240053335-eng.pdf?sequence=1>

- WHO.(2023). HIV - global. World Health Organization. Available at:https://www.who.int/health-topics/HIV-aids#tab=tab_1
- WHO.(2023). *HIV and AIDS*. World Health Organization. Available at: <https://www.who.int/news-room/fact-sheets/detail/HIV-aids>
- WHO.(2023). HIV statistics, globally and by WHO region, 2023. World Health Organization. Available at; <https://cdn.who.int/media/docs/default-source/hq-HIV-hepatitis-and-stis-library/j0294-who-HIV-epi-factsheet-v7.pdf>
- WHO.(2023). The role of HIV viral suppression in improving individual health and reducing transmission: policy brief. World Health Organization. Available at; <https://iris.who.int/bitstream/handle/10665/360860/9789240055179-eng.pdf?sequence=1>
- Widjaja, M. C. G. (2022). Rejimen KDT-ARV Terbaru dengan Dolutegravir. *Cermin Dunia Kedokteran*, 49(6), 314–319. <https://doi.org/10.55175/cdk.v49i6.239>
- Xavier Ruiz, F., & Arnold, E. 2020. Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. *Current opinion in structural biology*, 61, 113–123. <https://doi.org/10.1016/j.sbi.2019.11.011> ..
- Yee J, Patel P, Preuss CV. (2024) Efavirenz. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542316/>
- Zhong, M., Li, M., Qi, M., Su, Y., Yu, N., Lv, R., Ye, Z., Zhang, X., Xu, X., Cheng, C., Chen, C., & Wei, H. (2023). A retrospective clinical study of dolutegravir-versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China. *Frontiers in immunology*, 13, 1033098. <https://doi.org/10.3389/fimmu.2022.1033098> .